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Extended-spectrum beta-lactamase (ESBL) producing En-
terobacteriaceae infection reports are increasing due to ex-
tensive antibiotic consumption and widespread ESBL bacte-
rial gene — CTX-M, TEM and SHV mutation, determining
bacterial, mostly E. coli and K. pneumoniae, resistance
(Kim et al., 2002; Spanu et al., 2002; Thu Trang et al.,
2013; Shaikh et al., 2015).
Hospitalisation course and outcome in patients with ESBL
producing Enterobacteriaceae infection is considered less
favourable due to extensive antibacterial drug resistance
(Kim et al., 2002; Peralta et al., 2012). In order to choose
the best empirical antibiotic therapy, physicians should look
for factors that could indicate a less favourable hospitalisa-
tion course and outcome. An unfavourable hospitalisation
course and outcome in patients with ESBL producing En-
terobacteriaceae infection previously have been associated
with severe concomitant diseases, prior administration of
multiple antimicrobial agents, recent surgery, older age and
presence of indwelling catheters (Skippen et al., 2006;
Mehrgan et al., 2010).
The aim of this study was to identify additional possible
risk factors that could influence the hospitalisation course
and outcome in patients with ESBL producing Enterobacte-
riaceae infection. A cross-sectional single-centre study was
conducted in Rîga East Clinical University Hospital. All
consecutive ESBL producing Enterobacteriaceae infection
cases were selected during a 6-month period (2014). A total
of 136 ESBL producing Enterobacteriaceae infection cases
were included in the study. Demographic, hospitalisation
and clinical data were obtained from medical records on the
day patient was discharged. Disease data were encoded ac-
cording to the International Statistical Classification of Dis-
eases (ICD-10) (Anonymous, 2015). Biomaterial (urine,
bronchoalveolar washing, cerebrospinal fluid, wound swab,
sputum, blood, abdominal cavity fluid, abscess sample) for
bacteriological analysis was collected in transport medium
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Hospitalisation course and outcome for patients with extended-spectrum beta-lactamase (ESBL)
producing Enterobacteriaceae infection is less favourable due to extensive antibacterial resis-
tance. This study was conducted to identify possible risk factors that could influence the hospitali-
sation course and outcome in these patients. The study protocol included demographic, clinical,
hospitalisation, bacteriological and plasmid genetic data. The preliminary study results showed
that hospitalisation course and outcome was less favourable for internal medicine profile patients
with ESBL producing bacteria, TEM gene presence in the bacterial plasmid genome, patient age
< 65 years and patients with infectious and musculoskeletal diseases. The study includes pre-
liminary data only and further studies should be carried out to verify the suggested risk factors.
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and transported to the microbiological laboratory within 24
hours. In the laboratory, each sample was cultured. Identifi-
cation of the bacteria was conducted by a Vitex 2 Compact
system (bioMerieux, France) and susceptibility tests by the
disk diffusion method (Oxoid, UK; CLSI 2013). ESBL pro-
duction was confirmed using synergy tests with ESBL and
Amp-C inhibiting discs (Rosco, Denmark). Genetic analysis
provided information about CTX-M, TEM and SHV bacte-
rial gene presence in the ESBL producing Enterobacteri-
aceae plasmid genome. Bacteria selected from ESBL pro-
ducing Enterobacteriaceae colonies were grown in 2 ml
Lysogenic broth media at 37 °C overnight. Plasmid DNA
were isolated by manufacturer protocol using a E.Z.N.A.
plasmid Mini Kit I (Omega Bio-Tek, USA). CTX-M, SHV
and TEM bacterial plasmid gene detection was performed
using polymerase chain reaction (PCR) using gene specific
primers (Wu et al., 2001; Edelstein et al., 2003; Anony-
mous, 2013). CTX-M gene detection was conducted accord-
ing to Edelstein et al., 2003, SHV gene detection according
to Nüesch-Inderbinen et al. (1996), and TEM gene detec-
tion according to Du et al. (2013). PCR products were ana-
lysed using 2% agarose gel. A study protocol with 106 pa-
rameters was completed for each ESBL-producing
Enterobacteriaceae infection case and used for database de-
velopment and statistical analysis. All p values were
two-tailed and considered significant at the 5% level. The
study was conducted according to the Helsinki Declaration,
reviewed and approved by the local Ethics Committee.
ESBL producing Enterobacteriaceae were isolated from 52
(38.2%) female and 84 (61.8%) male patients at the mean
age of 61.35 ± 16.92 (CI 95% 57.76–64.78) years. Mostly
ESBL producing K. pneumoniae (n = 66, 48.53%) and E.
coli (n = 36, 26.47%) were isolated (Fig. 1), mainly from
wound (n = 44, 32.35%) biomaterial (Fig. 2), in most of the
cases (n = 132, 97.06%) containing CTX-M gene (Fig. 3).
In 42 cases (30.9%), ESBL-producing Enterobacteriaceae
were isolated from internal medicine profile department pa-
tients, in 94 cases (69.1%) from surgical profile department
patients. Patients with ESBL producing Enterobacteriaceae
infection spent an average of 60.29 ± 98.93 (CI 95%
30.82–98) days in the hospital. In 82 ESBL producing En-
terobacteriaceae infection cases (60.29%) patients were ad-
mitted to the ICU at least once and time spent there was on
average 18.57 ± 21.9 (CI 95% 10.89–26.86) days. In 54
cases (39.71%), patients were never admitted to ICU during
their hospitalisation period.
Comparison between hospitalisation course and outcome in
patients with ESBL producing Enterobacteriaceae infection
in internal medicine and surgical departments is presented
in Table 1.
TEM gene presence in ESBL producing Enterobacteriaceae
plasmid genome was associated with increased mortality,
compared to cases where the TEM gene was absent (p =
0.018). CTX-M and SHV gene presence in ESBL producing
Enterobacteriacea plasmid genome was not associated with
a statistically significant increase in mortality.
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Fig. 1. Isolated ESBL producing Enterobacteriaceae strains (%).
Fig. 2. Biomaterials from which ESBL producing bacteria were isolated
(%).
Fig. 3. Detected ESBL producing Enterobacteriaceae beta-lactamase
plasmid genes (%).
T a b l e 1
COMPARISON BETWEEN HOSPITALISATION COURSE AND OUT-
COME IN PATIENTS WITH ESBL PRODUCING
ENTEROBACTERIACEAE INFECTION IN INTERNAL MEDICINE
AND SURGICAL DEPARTMENTS
Internal medicine department Surgical department
More concomitant diseases (p < 0.001) More cases of sepsis (p < 0.001)
More days spent in ICU (p = 0.043) More cases of MODS (p = 0.001)
Increased mortality rate (p = 0.046) Death at a younger age (p = 0.01)
Patients with ESBL producing Enterobacteriaceae infection
aged < 65 years (p = 0.045) and concomitant infectious dis-
eases (p = 0.047) were more frequently admitted to the ICU.
Patients with ESBL producing Enterobacteriaceae infection
admitted to the ICU (p = 0.02) and suffering from musculo-
skeletal diseases (p = 0.002) had increased mortality.
A less favourable hospitalisation course and outcome was
observed in this study comparing to other literature sources:
mean hospital stay was almost three times longer (60 vs 24
days) (Wu et al., 2014), patients were at least three times
more often admitted to the ICU (60% vs 4–23%) (Concepts
et al., 2010), stayed there almost two times longer (19 vs 12
days) (Abdalla et al., 2014) and had a higher mortality rate
(21% vs 14%) (Peralta et al., 2012). This could be ex-
plained by the critically ill and immunocompromised pa-
tient predominance in the studied patient profile, including
patients with severe abdominal trauma, head trauma, ex-
tremity amputations and extensive bedsores, suggesting a
more severe clinical condition. Significantly more patients
in this study presented with shock (13% vs 6%) (Peralta et
al., 2012) and were older (70 years) than patients described
in the other literature sources (65 years) (Peralta et al.,
2012).
Musculoskeletal disease presence, hospitalisation in internal
medicine profile departments, and TEM bacterial gene pres-
ence were associated with increased mortality in this study
and could be considered as possible risk factors for less fa-
vourable hospitalisation course and outcome for patients
with ESBL producing Enterobacteriaceae infection. These
factors have not been studied as possible risk factors in any
studies previously. The CTM-X bacterial gene has been as-
sociated with increased mortality in patients with ESBL
producing Enterobacteriaceae infection in other studies
(Mehrgan et al., 2010); however, this association was not
observed in our study. Concomitant infectious diseases and
age less than 65 years predisposed patients with ESBL pro-
ducing Enterobacteriaceae infection for more frequent ad-
mission to the ICU in this study. Admission to the ICU has
been identified as a risk factor for increased mortality also
in other studies (Mayr et al., 2006; Du et al., 2013). There-
fore, infectious diseases and younger age might be consid-
ered as risk factors for a less favourable hospitalisation
course and outcome for patients with ESBL producing
Enterobacteriaceae infection.
The study includes preliminary data only and further studies
should be carried out to verify the suggested risk factors.
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RISKA FAKTORI, KAS NOSAKA SLIKTÂKU HOSPITALIZÂCIJAS GAITU UN IZNÂKUMU PACIENTIEM AR ESBL
PRODUCÇJOÐU ENTEROBACTERIACEAE DZIMTAS BAKTÇRIJU INFEKCIJU: SÂKOTNÇJIE REZULTÂTI
Hospitalizâcijas gaita un iznâkums pacientiem ar paplaðinâta spektra beta laktamâzi (ESBL) producçjoðo Enterobacteriaceae dzimtas
baktçriju infekciju ir nelabvçlîgâks plaðâs antibakteriâlâs rezistences dçï. Ðis pçtîjums tika veikts, lai noskaidrotu riska faktorus, kas varçtu
ietekmçt hospitalizâcijas gaitu un iznâkumu ðiem pacientiem. Pçtîjuma protokols ietvçra demogrâfiskos, klîniskos, hospitalizâcijas,
bakterioloìiskos un plazmîdu ìençtiskos datus. Pçtîjuma rezultâti parâdîja, ka hospitalizâcijas gaita un iznâkums mazâk labvçlîgs bija
terapeitiskâ profila pacientiem ar ESBL producçjoðo baktçriju infekciju, TEM gçna klâtbûtni baktçriju plazmîdu genomâ, pacientiem
vecumâ zem 65 gadiem, kâ arî pacientiem ar papildus infekcijas un balsta – kustîbu aparâta slimîbâm. Pçtîjums sniedz tikai sâkotnçjo
informâciju — nepiecieðami papildus pçtîjumi konstatçto riska faktoru izvçrtçðanai.
